Enhancing Pediatric Pain Management in Portuguese Emergency Departments: Progress and Challenges (2007-2018)

By João L. Carapinha

April 29, 2025

Pain assessment in Portuguese PEDs has seen substantial progress from 2007 to 2018. The adoption of local protocols and pain scales increased from 52% to 93%, based on a recently published study. However, pediatric pain management remains inadequate for mild to moderate pain, with only 22% of facilities consistently administering analgesia. Treatment for severe pain and opioid usage appears sufficient. Procedural sedation and analgesia have increased but are not universally practiced. Alarmingly, 88% of staff members recognize the need for enhanced training.

Advancements in Pain Assessment Practices

The implementation of pain assessment protocols and pain scales has increased dramatically:

  • Local pain management protocols rose from 52% in 2007 to 93% in 2018.
  • Pain scale usage reached 100% by 2018, showing a comprehensive approach.
  • By 2018, nurses became the primary pain assessors in all hospitals.

This improvement reflects the application of national guidelines after Portugal’s National Plan Against Pain (2001) and pediatric-specific guidelines.

Ongoing Challenges in Effective Pain Treatment

Despite assessment advancements, pain management still faces obstacles. More hospitals treat mild to moderate pain at least 50% of the time (91% in 2018 vs. 57% in 2007). Yet only 22% always provide analgesia, down from 43% in 2007. Analgesia for procedures remains underused: i) venipuncture analgesia is rarely given (83% never used it in 2018), ii) lumbar puncture analgesia saw no improvement, iii) fracture reduction and wound suture pain management improved. Use increased from 52% to 83%, but ethical concerns persist. Forced immobilization was reported in 26% of hospitals.

Importance of Addressing Pediatric Pain

Pain affects over 60% of PED admissions, making it critical in emergency care. Despite global awareness, pediatric pain management remains inadequate. Untreated pain can cause immediate anxiety and delayed care, plus long-term emotional harm and chronic pain risks. Since Portugal’s National Plan Against Pain (2001) and pediatric guidelines (2010), policy efforts have improved. However, local implementation varies.

The WHO states pain relief is a fundamental right and that inadequate management is substandard care. WHO guidelines recommend multimodal pediatric pain management, blending pharmacological and non-pharmacological methods.

Implications for Healthcare Quality and Economics

Cost Implications of Inadequate Pain Management

Poor pain management may lead to longer emergency stays, more return visits, extra resources for complications, higher long-term costs.

Necessity for Training and Resource Allocation

The study shows a demand for training (88% of staff seek more). Effective programs require staff education, protocol development, quality monitoring, and medication availability.

Future Research Directions

To address gaps, healthcare systems should:

  1. Standardize Protocols: Universal pain assessment and triage protocols.
  2. Invest in Education: Targeted training on opioid fears and symptom masking.
  3. Promote Quality Improvements: Regular audits and feedback.
  4. Allocate Resources Wisely: Ensure analgesic access in all PEDs.
  5. Encourage Research: Study cost-effectiveness and long-term outcomes.

While progress has been made in Portuguese PEDs, more work is needed to improve pain management. For details, see the original study here.

Reference url

Recent Posts

peanut oral immunotherapy
        

Promising Results for Peanut Oral Immunotherapy

🌟 Ready to change the conversation on peanut allergies?

A recent study from the University of Virginia shines a light on peanut oral immunotherapy (epOIT), revealing that 90% of young children achieved effective desensitization with minimal side effects. This compelling research advocates for early intervention, potentially transforming how we manage this prevalent food allergy.

Dive into the full article to explore how adopting this approach could reshape health policies and enhance quality of life for affected families.

#SyenzaNews #HealthTech #HealthcareInnovation

ZEVASKYN gene therapy
         

ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis Bullosa

🌟 What if a single treatment could dramatically change the lives of patients with a rare genetic skin disorder?

The FDA’s recent approval of **ZEVASKYN gene therapy** is a groundbreaking advancement for those suffering from recessive dystrophic epidermolysis bullosa (RDEB). This innovative therapy not only promotes significant wound healing and pain reduction but also represents a hopeful new avenue for individuals facing chronic wounds due to this debilitating condition.

Curious about its implications for healthcare and patient access? Dive into the full article to learn more about this transformative solution!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

nipocalimab myasthenia gravis
   

Nipocalimab for Myasthenia Gravis Treatment

🚀 Have you heard about the latest advancement in myasthenia gravis treatment?

The FDA’s approval of nipocalimab (Imaavy) marks a significant milestone, as it’s the first FcRn blocker authorized for both adults and pediatric patients with generalized myasthenia gravis who have specific autoantibodies. This innovative therapy not only demonstrates impressive clinical efficacy but also expands treatment options for those battling this challenging autoimmune disorder.

Curious about how nipocalimab could reshape patient care and healthcare economics? Discover all the insights in the full article!

#SyenzaNews #pharmaceuticals #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.